May 2026
Six Randomized Studies Shows Significant Vision Gains with RevitalVision Across Eye Conditions
The growing body of clinical evidence for RevitalVision supports the integration of perceptual learning into routine clinical practice, particularly for patients who have exhausted conventional treatment options and the clinician and patient remain unsatisfied with their current best-corrected vision.
Read the full article in Ophthalmology Management
January 2026
RevitalVision Demonstrates Efficacy and Safety in Infantile Nystagmus
August 2025
RevitalVision Takes Vision to the Next Level for Elite Professional Athletes!
We’re proud to share the results from a new randomized controlled trial using RevitalVision’s digital training program, this time, with professional footballers from Standard de Liège, a Premier League Belgian team. The footballers experienced significant improvements in visual acuity, contrast sensitivity, and stereoacuity.
These enhancements may provide a competitive advantage with stronger overall performance on the field.
June 2025
NASCAR Driver Joey Gase Endorses RevitalVision
Joey Gase, NASCAR driver and co-owner of Emerling-Gase Motorsports, is championing RevitalVision’s clinically proven digital training therapies. Gase—who was diagnosed with keratoconus in 2020—is helping to raise awareness about the importance of early detection and treatment of related eye conditions, while advocating for proactive eye health.
Read more
April 2025
RevitalVision Wins Three First Place Awards at ASCRS 2025
Three First Place awards were given to RevitalVision clinical studies at ASCRS 2025, recognizing breakthroughs in Keratoconus and MF-IOL vision improvement.
Congratulations to Dr. Lionel Raj (2 awards) and Dr. Adi Einan-Lifshitz for presenting these outstanding, award-winning studies.
This achievement highlights the growing clinical impact of RevitalVision’s non-invasive, neuroplasticity-based vision therapy.
